Cholesterol-T7-PEG2-DP7 peptide
Sequence: cholesterol-HAIYPRH-PEG2-VQWRIRVAVIRK
siRNA (Cy5-labeled for biodistribution imaging)
| Experiment Id | EXP002007 |
|---|---|
| Paper | A blood–brain barrier- and blood–brain tumor barrier-penetrating siRNA delivery system targeting gli |
| Peptide | Cholesterol-T7-PEG2-DP7 peptide |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 1 mg/kg cy5-siRNA i.v.; 4 h biodistribution readout. |
| Mixing Ratio | Peptide:siRNA mass ratio 10:1 (incubated before i.v. administration). |
| Formulation Format | Cholesterol-peptide/siRNA complex (electrostatic) |
| Formulation Components | Cholesterol-T7-PEG2-DP7 peptide complexed with cy5-siRNA for BBB/BBTB penetration screening. PEG2 linker; T7 head. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Normal mice and/or GL261 tumor-bearing mice (biodistribution imaging at 4 h). |
| Administration Route | Intravenous (i.v.) single dose; organs collected at 4 h for IVIS imaging and brain section CLSM. |
| Output Type | In vivo biodistribution: brain fluorescence signal after i.v. administration (BBB/BBTB penetration screening). |
| Output Value | Brain accumulation signal detected; DAT (DP7-ACP-T7) reported as strongest among tested peptide/linker configurations. |
| Output Units | |
| Output Notes | Screening used DP7 and T7 as target heads with different linkers (ACP, PEG2, Gly6) and orientations. |
| Toxicity Notes | |
| Curation Notes |